{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:04:19Z","timestamp":1795122259016,"version":"4.10.3"},"reference-count":45,"publisher":"American Society of Hematology","issue":"12","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cells directed against CD19 (CAR19) are a revolutionary treatment for B-cell lymphomas (BCLs). CAR19 cell expansion is necessary for CAR19 function but is also associated with toxicity. To define the impact of CAR19 expansion on patient outcomes, we prospectively followed a cohort of 236 patients treated with CAR19 (brexucabtagene autoleucel or axicabtagene ciloleucel) for mantle cell lymphoma (MCL), follicular lymphoma, and large BCL (LBCL) over the course of 5 years and obtained CAR19 expansion data using peripheral blood immunophenotyping for 188 of these patients. CAR19 expansion was higher in patients with MCL than other lymphoma histologic subtypes. Notably, patients with MCL had increased toxicity and required fourfold higher cumulative steroid doses than patients with LBCL. CAR19 expansion was associated with the development of cytokine release syndrome, immune effector cell\u2013associated neurotoxicity syndrome, and the requirement for granulocyte colony-stimulating factor 14\u00a0days after infusion. Younger patients and those with elevated lactate dehydrogenase (LDH) had significantly higher CAR19 expansion. In general, no association between CAR19 expansion and LBCL treatment response was observed. However, when controlling for tumor burden, we found that lower CAR19 expansion in conjunction with low LDH was associated with improved outcomes in LBCL. In sum, this study finds CAR19 expansion principally associates with CAR-related toxicity. Additionally, CAR19 expansion as measured by peripheral blood immunophenotyping may be dispensable to favorable outcomes in LBCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012637","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T19:09:01Z","timestamp":1710788941000},"page":"3314-3326","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity"],"prefix":"10.1182","volume":"8","author":[{"given":"Mark P.","family":"Hamilton","sequence":"first","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"3Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Craig","sequence":"additional","affiliation":[{"name":"4Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-8154","authenticated-orcid":false,"given":"Cesar","family":"Gentille Sanchez","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mina","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tamaresis","sequence":"additional","affiliation":[{"name":"4Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-7919","authenticated-orcid":false,"given":"Nadia","family":"Kirmani","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Ehlinger","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6992-8815","authenticated-orcid":false,"given":"Shriya","family":"Syal","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-5771","authenticated-orcid":false,"given":"Zinaida","family":"Good","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"4Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Sworder","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Schroers-Martin","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-8962","authenticated-orcid":false,"given":"Ying","family":"Lu","sequence":"additional","affiliation":[{"name":"4Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett","family":"Meyer","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shizuru","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-0381","authenticated-orcid":false,"given":"Melody","family":"Smith","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-4651","authenticated-orcid":false,"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tibshirani","sequence":"additional","affiliation":[{"name":"4Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"5Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA"},{"name":"6Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"26","key":"2024062515202420000_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024062515202420000_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024062515202420000_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024062515202420000_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2024062515202420000_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2024062515202420000_bib6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"2024062515202420000_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024062515202420000_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024062515202420000_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024062515202420000_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"2024062515202420000_bib11","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2024062515202420000_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2024062515202420000_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2024062515202420000_bib14","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024062515202420000_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2022","journal-title":"Cancer Cell"},{"issue":"9","key":"2024062515202420000_bib16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"issue":"27","key":"2024062515202420000_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024062515202420000_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024062515202420000_bib19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"2024062515202420000_bib20","doi-asserted-by":"crossref","first-page":"e57838","DOI":"10.1371\/journal.pone.0057838","article-title":"Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials","volume":"8","author":"Jena","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2024062515202420000_bib21","first-page":"1","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J\u00a0Stat Softw"},{"issue":"13","key":"2024062515202420000_bib22","first-page":"1","article-title":"lmerTest package: tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J\u00a0Stat Softw"},{"key":"2024062515202420000_bib23","unstructured":"Therneau\n              T\n            \n          . A package for survival analysis in R. R Package version 3.5-8. 2024. Accessed 5 April 2024. https:\/\/CRAN.R-project.org\/package=survival."},{"issue":"1","key":"2024062515202420000_bib24","first-page":"1","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J\u00a0Stat Softw"},{"issue":"514","key":"2024062515202420000_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/01621459.2015.1108848","article-title":"Exact post-selection inference for sequential regression procedures","volume":"111","author":"Tibshirani","year":"2016","journal-title":"Journal of the American Statistical Association"},{"issue":"4","key":"2024062515202420000_bib26","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ije\/dyz032","article-title":"Accounting for missing data in statistical analyses: multiple imputation is not always the answer","volume":"48","author":"Hughes","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"5","key":"2024062515202420000_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2024062515202420000_bib28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2023-179868","article-title":"Five year outcomes of patients with large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel: results from the US Lymphoma CAR-T Cell Consortium","volume":"142","author":"Spiegel","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024062515202420000_bib29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"2024062515202420000_bib30","doi-asserted-by":"publisher","DOI":"10.1101\/674259","article-title":"Pathognomonic and epistatic genetic alterations in B-cell non-Hodgkin lymphoma","author":"Man","year":"19  2019","journal-title":"bioRxiv"},{"issue":"3","key":"2024062515202420000_bib31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2020.274258","article-title":"Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma","volume":"107","author":"Ma","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2024062515202420000_bib32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"22","key":"2024062515202420000_bib33","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024062515202420000_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40164-021-00248-9","article-title":"Elevated LDH greater than 400 U\/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort","volume":"10","author":"Rabinovich","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"27","key":"2024062515202420000_bib35","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"514","key":"2024062515202420000_bib36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/01621459.2015.1108848","article-title":"Exact post-selection inference for sequential regression procedures","volume":"111","author":"Tibshirani","year":"2016","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"1","key":"2024062515202420000_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J\u00a0Transl Med"},{"issue":"8","key":"2024062515202420000_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2174\/1389202921999200716103758","article-title":"Discrepant mRNA and protein expression in immune cells","volume":"21","author":"Li","year":"2020","journal-title":"Curr Genomics"},{"issue":"6","key":"2024062515202420000_bib39","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.hoc.2023.05.007","article-title":"Chimeric antigen receptor T-cell therapy in aggressive B-cell lymphoma","volume":"37","author":"Hamilton","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"issue":"19","key":"2024062515202420000_bib40","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2024062515202420000_bib41","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T-cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"key":"2024062515202420000_bib42","doi-asserted-by":"crossref","first-page":"539654","DOI":"10.3389\/fimmu.2020.539654","article-title":"4-1BB signaling boosts the anti-tumor activity of CD28-incorporated 2(nd) generation chimeric antigen receptor-modified T cells","volume":"11","author":"Dai","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2024062515202420000_bib43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality","volume":"21","author":"Smith","year":"2023","journal-title":"J\u00a0Transl Med"},{"issue":"4","key":"2024062515202420000_bib44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2024062515202420000_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","article-title":"Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7)","volume":"5","author":"Filosto","year":"2024","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3314\/2232132\/blooda_adv-2024-012637-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3314\/2232132\/blooda_adv-2024-012637-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:21:05Z","timestamp":1719328865000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/12\/3314\/515342\/CAR19-monitoring-by-peripheral-blood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012637","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}